Stock Quote

Neal Fowler sees big things for Envisia and glaucoma treatment in 2015

If all goes to plan, 2015 will be a big year for Neal Fowler and Durham’s Envisia Therapeutics. The drug developer spun out of Liquidia Technologies late last year to work on new drugs targeted at glaucoma and cataracts...
Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.